|
1
|
Hahn WC and Weinberg RA: Rules for making
human tumor cells. N Engl J Med. 347:1593–1603. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hommes DW, Peppelenbosch MP and van
Deventer SJ: Mitogen activated protein (MAP) kinase signal
transduction pathways and novel anti-inflammatory targets. Gut.
52:144–151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Freeman M: Feedback control of
intercellular signalling in development. Nature. 408:313–319. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Casci T, Vinós J and Freeman M: Sprouty,
an intracellular inhibitor of Ras signaling. Cell. 96:655–665.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hacohen N, Kramer S, Sutherland D, Hiromi
Y and Krasnow MA: sprouty encodes a novel antagonist of FGF
signaling that patterns apical branching of the Drosophila airways.
Cell. 92:253–263. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guy GR, Jackson RA, Yusoff P and Chow SY:
Sprouty proteins: Modified modulators, matchmakers or missing
links? J Endocrinol. 203:191–202. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Basson MA, Akbulut S, Watson-Johnson J,
Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T,
McMahon AP, et al: Sprouty1 is a critical regulator of
GDNF/RET-mediated kidney induction. Dev Cell. 8:229–239. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shim K, Minowada G, Coling DE and Martin
GR: Sprouty2, a mouse deafness gene, regulates cell fate decisions
in the auditory sensory epithelium by antagonizing FGF signaling.
Dev Cell. 8:553–564. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Taketomi T, Yoshiga D, Taniguchi K,
Kobayashi T, Nonami A, Kato R, Sasaki M, Sasaki A, Ishibashi H,
Moriyama M, et al: Loss of mammalian Sprouty2 leads to enteric
neuronal hyperplasia and esophageal achalasia. Nat Neurosci.
8:855–857. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taniguchi K, Ayada T, Ichiyama K, Kohno R,
Yonemitsu Y, Minami Y, Kikuchi A, Maehara Y and Yoshimura A:
Sprouty2 and Sprouty4 are essential for embryonic morphogenesis and
regulation of FGF signaling. Biochem Biophys Res Commun.
352:896–902. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang S, Lin Y, Itäranta P, Yagi A and
Vainio S: Expression of Sprouty genes 1, 2 and 4 during mouse
organogenesis. Mech Dev. 109:367–370. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Masoumi-Moghaddam S, Amini A and Morris
DL: The developing story of Sprouty and cancer. Cancer Metastasis
Rev. 33:695–720. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Barbáchano A, Ordóñez-Morán P, Garcia JM,
Sánchez A, Pereira F, Larriba MJ, Martínez N, Hernández J, Landolfi
S, Bonilla F, et al: SPROUTY-2 and E-cadherin regulate reciprocally
and dictate colon cancer cell tumourigenicity. Oncogene.
29:4800–4813. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holgren C, Dougherty U, Edwin F, Cerasi D,
Taylor I, Fichera A, Joseph L, Bissonnette M and Khare S: Sprouty-2
controls c-Met expression and metastatic potential of colon cancer
cells: Sprouty/c-Met upregulation in human colonic adenocarcinomas.
Oncogene. 29:5241–5253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schaaf G, Hamdi M, Zwijnenburg D, Lakeman
A, Geerts D, Versteeg R and Kool M: Silencing of SPRY1 triggers
complete regression of rhabdomyosarcoma tumors carrying a mutated
RAS gene. Cancer Res. 70:762–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sutterluty H, Mayer CE, Setinek U, Attems
J, Ovtcharov S, Mikula M, Mikulits W, Micksche M and Berger W:
Down-regulation of Sprouty2 in non-small cell lung cancer
contributes to tumor malignancy via extracellular signal-regulated
kinase pathway-dependent and -independent mechanisms. Mol Cancer
Res. 5:509–520. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McKie AB, Douglas DA, Olijslagers S,
Graham J, Omar MM, Heer R, Gnanapragasam VJ, Robson CN and Leung
HY: Epigenetic inactivation of the human sprouty2 (hSPRY2)
homologue in prostate cancer. Oncogene. 24:2166–2174. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fritzsche S, Kenzelmann M, Hoffmann MJ,
Müller M, Engers R, Gröne HJ and Schulz WA: Concomitant
down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr
Relat Cancer. 13:839–849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ,
Phillips WA, Yang H, Wong ES, Leong HF, Zeng Q, et al: The
ras/mitogen-activated protein kinase pathway inhibitor and likely
tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated
in breast cancer. Cancer Res. 64:6127–6136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fong CW, Chua MS, McKie AB, Ling SH, Mason
V, Li R, Yusoff P, Lo TL, Leung HY, So SK and Guy GR: Sprouty 2, an
inhibitor of mitogen-activated protein kinase signaling, is
down-regulated in hepatocellular carcinoma. Cancer Res.
66:2048–2058. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masoumi-Moghaddam S, Amini A, Wei AQ,
Robertson G and Morris DL: Sprouty 2 protein, but not Sprouty 4, is
an independent prognostic biomarker for human epithelial ovarian
cancer. Int J Cancer. 137:560–570. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwabi-Addo B, Wang J, Erdem H, Vaid A,
Castro P, Ayala G and Ittmann M: The expression of Sprouty1, an
inhibitor of fibroblast growth factor signal transduction, is
decreased in human prostate cancer. Cancer Res. 64:4728–4735. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Masoumi-Moghaddam S, Amini A, Wei AQ,
Robertson G and Morris DL: Sprouty 1 predicts prognosis in human
epithelial ovarian cancer. Am J Cancer Res. 5:1531–1541.
2015.PubMed/NCBI
|
|
24
|
Rathmanner N, Haigl B, Vanas V, Doriguzzi
A, Gsur A and Sutterlüty-Fall H: Sprouty2 but not Sprouty4 is a
potent inhibitor of cell proliferation and migration of
osteosarcoma cells. FEBS Lett. 587:2597–2605. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jäggi F, Cabrita MA, Perl AK and
Christofori G: Modulation of endocrine pancreas development but not
beta-cell carcinogenesis by Sprouty4. Mol Cancer Res. 6:468–482.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tennis MA, Van Scoyk MM, Freeman SV,
Vandervest KM, Nemenoff RA and Winn RA: Sprouty-4 inhibits
transformed cell growth, migration and invasion, and
epithelial-mesenchymal transition, and is regulated by Wnt7A
through PPARgamma in non-small cell lung cancer. Mol Cancer Res.
8:833–843. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vanas V, Mühlbacher E, Kral R and
Sutterlüty-Fall H: Sprouty4 interferes with cell proliferation and
migration of breast cancer-derived cell lines. Tumour Biol.
35:4447–4456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Faratian D, Sims AH, Mullen P, Kay C, Um
I, Langdon SP and Harrison DJ: Sprouty 2 is an independent
prognostic factor in breast cancer and may be useful in stratifying
patients for trastuzumab therapy. PLoS One. 6:e237722011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding W, Bellusci S, Shi W and Warburton D:
Genomic structure and promoter characterization of the human
Sprouty4 gene, a novel regulator of lung morphogenesis. Am J
Physiol Lung Cell Mol Physiol. 287:52–59. 2004. View Article : Google Scholar
|
|
30
|
Khaitan D, Dinger ME, Mazar J, Crawford J,
Smith MA, Mattick JS and Perera RJ: The melanoma-upregulated long
noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer
Res. 71:3852–3862. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berger W, Elbling L, Hauptmann E and
Micksche M: Expression of the multidrug resistance-associated
protein (MRP) and chemoresistance of human non-small-cell lung
cancer cells. Int J Cancer. 73:84–93. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haigl B, Mayer CE, Siegwart G and
Sutterlüty H: Sprouty4 levels are increased under hypoxic
conditions by enhanced mRNA stability and transcription. Biol Chem.
391:813–821. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kral RM, Mayer CE, Vanas V, Gsur A and
Sutterlüty-Fall H: In non-small cell lung cancer mitogenic
signaling leaves Sprouty1 protein levels unaffected. Cell Biochem
Funct. 32:96–100. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sirivatanauksorn Y, Sirivatanauksorn V,
Srisawat C, Khongmanee A and Tongkham C: Differential expression of
sprouty genes in hepatocellular carcinoma. J Surg Oncol.
105:273–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Thompson B, Ren C, Ittmann M and
Kwabi-Addo B: Sprouty4, a suppressor of tumor cell motility, is
down regulated by DNA methylation in human prostate cancer.
Prostate. 66:613–624. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Doriguzzi A, Haigl B, Gsur A and
Sutterlüty-Fall H: The increased Sprouty4 expression in response to
serum is transcriptionally controlled by Specific protein 1. Int J
Biochem Cell Biol. 64:220–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mayer CE, Haigl B, Jantscher F, Siegwart
G, Grusch M, Berger W and Sutterlüty H: Bimodal expression of
Sprouty2 during the cell cycle is mediated by phase-specific
Ras/MAPK and c-Cbl activities. Cell Mol Life Sci. 67:3299–3311.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
So WK, Cheng JC, Liu Y, Xu C, Zhao J,
Chang VT and Leung PC: Sprouty4 mediates amphiregulin-induced
down-regulation of E-cadherin and cell invasion in human ovarian
cancer cells. Tumour Biol. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang H, Guo Q, Wang X, Wang C, Zhao X and
Li M: Aberrant expression of hSef and Sprouty4 in endometrial
adenocarcinoma. Oncol Lett. 11:45–50. 2016.PubMed/NCBI
|
